Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
August 06, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy™ Expected in 2H 2020 MolMed and GSK Agreements...
Orchard Therapeutics to Present at Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Wedbush...
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results
July 30, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
July 20, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has received both orphan drug designation and...
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK
July 15, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide...
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
July 09, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON and MILAN, Italy, July 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, and MolMed S.p.A (MLMD.MI), one of the company’s principal...
Orchard Therapeutics to Present at Virtual Investor Conferences in June
May 27, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 27, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that presentations by the management team will be made at the...
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
May 15, 2020 06:00 ET
|
Orchard Therapeutics (Europe) Limited
First Primary Outcome Measure Met with All Eight Patients Achieving Hematologic Engraftment Improved Motor Skills, Stable Cognitive Scores and Normal Growth Seen in First Two Patients One-year...
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
May 07, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Portfolio Investments More Tightly Prioritized Around High Need, High Value Indications First Disease Targets Extending Platform into Less Rare Indications Disclosed Updated Timelines Provided for...
Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results
May 01, 2020 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...